Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 3, 2014, Pages 639-649

  Yung, Raymond ^a   Seyfoddin, Vahid ^a   Guise, Christopher ^a   Tijono, Sofian ^a   McGregor, Ailsa ^b   Connor, Bronwen ^b   Ching, Lai Ming ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

DMXAA; Glioblastomas; Intracranial; Lenalidomide; Vascular disrupting

Indexed keywords

LENALIDOMIDE; LUCIFERASE; VADIMEZAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN NECROSIS; BRAIN TISSUE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; FLUORESCENCE IMAGING; GLIOBLASTOMA; GLIOMA CELL; HISTOPATHOLOGY; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TUMOR NECROSIS; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GLIOMA; INFUSIONS, SUBCUTANEOUS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RANDOM ALLOCATION; THALIDOMIDE; XANTHONES;

EID: 84896052957     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2395-y     Document Type: Article

References (48)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
2. Khasraw M, Lassman AB (2010) Advances in the treatment of malignant gliomas. Curr Oncol Rep 12:26-33
3. Chaudhry IH, O'Donovan DG, Brenchley PEC, Reid H, Roberts ISD (2001) Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 39:409-415 (Pubitemid 32990094)
4. Cloughesy TF, Prados MD, Wen PY, Mikkelsen T, Abrey LE, Schiff D, Yung WK, Maoxia Z, Dimery I, Friedman HS (2008) A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 26:2010b
5. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610-2621 (Pubitemid 44511625)
6. Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P (2009) Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival: clinical article. J Neurosurg 110:173-180
7. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurol 70:779-787
8. Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients a meta-analysis. J Am Med Assoc 305:487-494
9. Gerstner ER, Chen P-J, Wen PY, Jain RK, Batchelor TT, Sorensen G (2010) Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol 12:466-472
10. Ching L-M, Zwain S, Baguley BC (2004) Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 90:906-910 (Pubitemid 38406605)
11. Zhao L, Ching L-M, Kestell P, Baguley BC (2002) The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 87:465-470 (Pubitemid 34983572)
12. Thomsen LL, Ching L-M, Zhuang L, Gavin JB, Baguley BC (1991) Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 51:77-81
13. Folaron M, Kalmuk J, Lockwood J, Frangou C, Vokes J, Turowski SG, Merzianu M, Rigual NR, Sullivan-Nasca M, Kuriakose MA, Hicks WL Jr, Singh AK, Seshadri M (2013) Vascular priming enhances chemotherapeutic efficacy against head and neck cancer. Oral Oncol 49:893-902
14. Kanwar JR, Kanwar RK, Pandey S, Ching L-M, Krissansen GW (2001) Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer Res 61:1948-1956 (Pubitemid 32692012)
15. Matthews KE, Hermans IF, Roberts JM, Ching L-M, Ronchese F (2006) 5,6-Dimethylxanthenone-4-acetic acid treatment of a nonimmunogenic tumour does not synergize with active or passive CD8 + T-cell immunotherapy. Immunol Cell Biol 84:383-389 (Pubitemid 43882844)
16. Seshadri M, Ciesielski MJ (2009) MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas. J Cereb Blood Flow Metab 29:1373-1382
17. Lara PN, Douillard J-Y, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo D-S, Fan X (2011) Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 29:2965-2971
18. Conlon J, Burdette DL, Sharma S, Bhat N, Thompson M, Jiang Z, Rathinam VAK, Monks B, Jin T, Xiao TS, Vogel SN, Vance RE, Fitzgerald KA (2013) Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethyl-xanthenone-4-acetic acid. J Immunol 190:5216-5225
19. Prantner D, Perkins DJ, Lai W, Williams MS, Sharma S, Fitzgerald KA, Vogel SN (2012) 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem 287:39776-39788
20. Tijono SM, Guo K, Henare K, Palmer BD, Wang LS, Albelda SM, Ching L-M (2013) Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Br J Cancer 108:1306-1315
21. Knight R (2005) IMiDs: a novel class of immunomodulators. Semin Oncol 32(suppl 5):S24-S30
22. Ching L-M, Xu ZF, Gummer BH, Palmer BD, Joseph WR, Baguley BC (1995) Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 72:339-343
23. Chung F, Wang L-C, Kestell P, Baguley B, Ching L-M (2004) Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4- acetic acid (DMXAA) in mice: the role of tumour necrosis factor. Cancer Chemother Pharmacol 53:377-383 (Pubitemid 38553658)
24. Kestell P, Zhao L, Baguley BC, Palmer BD, Muller G, Paxton JW, Ching L-M (2000) Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. Cancer Chemother Pharmacol 46:135-141 (Pubitemid 30627476)
25. Rewcastle GW, Atwell GJ, Zhuang L, Baguley BC, Denny WA (1991) Potential antitumour agents. 61. Structure-activity relationships for in vivo colon 38 activity among disusbstituted 9-Oxo-9H-xanthene-4-acetic acids. J Med Chem 34:217-221
26. Muller GW, Stirling DI, Chen R (1997) US patent 5635517
27. Hobbs S, Jitrapakdee S, Wallace JC (1998) Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1α promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun 252:368-372 (Pubitemid 28542893)
28. Zhang X, Zhao M, Rudek MA, He P, Vogelstein B (2007) Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of DMXAA in human and mouse plasma. J Chromatogr 852:217-222 (Pubitemid 46830113)
29. Pather K, Helsby NA, Palmer BD, Ching L-M (2011) Development and validation of an high performance liquid chromatography assay for the determination of a fluorinated analogue of thalidomide, N-(2,6-dioxopiperidin-3- yl)-3,4,5,6- tetrafluorophthalamic acid and lenalidomide. J Liq Chromatogr Relat Technol 34:83-92
30. Baguley BC (2003) Antivascular therapy of cancer: DMXAA. Lancet Oncol 4:141-148
31. Ding Q, Kestell P, Baguley BC, Palmer BD, Paxton JW, Muller G, Ching L-M (2002) Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide. Cancer Chemother Pharmacol 50:186-192 (Pubitemid 35013656)
32. Cao Z, Joseph WR, Browne WL, Mountjoy KG, Palmer BD, Baguley BC, Ching L-M (1999) Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and antitumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 80:716-723 (Pubitemid 29209834)
33. Hofman FM, Chen TC (2010) The basic science of Avastin (Bevacizumab) therapy. In: Chen TC (ed) Controversies in neurooncology. Bentham Science Publishers, Avastin and Malignant Gliomas, pp 1-6
34. Wang L-CS, Thomsen L, Sutherland R, Reddy CB, Tijono SM, Chen C-JJ, Angel CE, Dunbar PR, Ching L-M (2009) Neutrophil influx and chemokine production during early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404). Neoplasia 8:793-803
35. Banks WA (2005) Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm Des 11:973-984
36. Rosenberg GA, Estrada EY, Dencoff JE, Stetler-Stevenson WG (1995) Tumor necrosis factor-α-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res 703:151-155 (Pubitemid 3013581)
37. Warth A, Kröger S, Wolburg H (2004) Redistribution of aquaporin-4 in human glioblastoma correlates with loss of agrin immunoreactivity from brain capillary basal laminae. Acta Neuropathol 107:311-318 (Pubitemid 38477357)
38. On NH, Mitchell R, Savant SD, Bachmeier CJ, Hatch GM, Miller DW (2012) Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model. J Neurooncol 111:133-143
39. Ching L-M, Browne WL, Tchnernegovski R, Gregory T, Baguley BC, Palmer BD (1998) Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity. Br J Cancer 78:336-343 (Pubitemid 28336419)
40. Ando Y, Fuse E, Figg WD (2002) Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8:1964-1973 (Pubitemid 34633760)
41. Zhou SF, Tingle MD, Kestell P, Paxton JW (2002) Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo. Xenobiotica 32:87-107 (Pubitemid 34155217)
42. Yu LJ, Drewes P, Gustafsson K, Brain EC, Hecht JE, Waxman DJ (1999) In vivo modulation of alternative pathways of P-450-catalysed cyclophosphamide metabolism: impact on pharmacokinetics and antitumour activity. J Pharmacol Exp Ther 288:928-937 (Pubitemid 29254128)
43. Kumar G, Lau H, Laskin O (2009) Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction. Cancer Chemother Pharmacol 63:1171-1175
44. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708
45. Fine HA, Kim L, Albert PS, Duic JP, Ma H, Zhang W, Tohnya T, Figg WD, Royce C (2007) A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res 13:7101-7106 (Pubitemid 350276894)
46. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H (2010) Identification of a primary target of thalidomide teratogenicity. Science 327:1345-1350
47. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26:2326-2335
48. Chung F, Lu J, Palmer BD, Kestell P, Browett P, Baguley BC, Tingle M, Ching L-M (2004) Thalidomide pharmacokinetics and metabolite formation in mice, rabbits and multiple myeloma patients. Clin Cancer Res 10:5949-5956 (Pubitemid 39180977)